Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abemaciclib
Drug ID BADD_D02498
Description Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947]. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
Indications and Usage * Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Marketing Status Not Available
ATC Code L01EF03
DrugBank ID DB12001
KEGG ID D10688
MeSH ID C000590451
PubChem ID 46220502
TTD Drug ID D05SBO
NDC Product Code 0002-6216; 0002-4483; 63419-0578; 54893-0098; 0110-4815; 0110-5337; 63419-0554; 0110-6216; 0002-5337; 0002-4815; 0110-4483
Synonyms abemaciclib | 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)pyrimidin-2-yl)amine | 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine | LY2835219 | LY-2835219 | LY2385219 | abemaciclib mesylate | LY2835210 | Verzenio
Chemical Information
Molecular Formula C27H32F2N8
CAS Registry Number 1231929-97-7
SMILES CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.002664%Not Available
Abdominal distension07.01.04.0010.001332%
Abdominal pain07.01.05.0020.005328%
Abdominal pain upper07.01.05.0030.005595%
Alopecia23.02.02.0010.005861%
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Arthralgia15.01.02.001--
Asthenia08.01.01.0010.005328%Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Blister23.03.01.001; 12.01.06.0020.000799%Not Available
Blood creatinine increased13.13.01.0040.001865%
Blood glucose decreased13.02.02.0010.000533%Not Available
Blood magnesium decreased13.11.01.0080.000533%Not Available
Blood potassium decreased13.11.01.0100.001066%Not Available
Blood pressure decreased13.14.03.002--Not Available
Bone pain15.02.01.0010.000799%
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation17.02.06.001; 08.01.09.0290.001066%Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.0010.004263%
Cough22.02.03.001--
Cystitis20.03.02.002; 11.01.14.0010.000799%
Death08.04.01.001--
Dehydration14.05.05.0010.013054%
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages